Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation

Running, not enrolling

Conditions studied: Transplant Complication

In brief

To develop a prospective quantitative liver allograft monitoring protocol and retrospectively validate the use of Phenotypic personalized medicine (PPM) in immunosuppression dosing in liver transplant recipients.

Key facts

Study ID

NCT06063213

Run by

University of Florida

People needed

40

Starts

2023-12-15

Expected to finish

2026-10-15

Last updated by the study team

2026-03-04

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• At least 18 years of age
• At least one-month post-transplant
• Recipient of a liver transplant alone or a simultaneous liver-kidney transplant

You may not qualify if…

• Unwilling to provide informed consent
• Recipient of a previous bone marrow or stem cell transplant
• Pregnant
• Unlikely to be able to comply with the study requirements, as determined by the PI

Where it is running

• University of Florida — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.